1BSL01AE Stock Overview
Operates as a pharmaceutical manufacturing company in Slovakia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Biotika a.s. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.00 |
| 52 Week High | €25.00 |
| 52 Week Low | €21.80 |
| Beta | 0.038 |
| 1 Month Change | -3.36% |
| 3 Month Change | 0% |
| 1 Year Change | 0.88% |
| 3 Year Change | -37.84% |
| 5 Year Change | -24.34% |
| Change since IPO | -97.07% |
Recent News & Updates
Shareholder Returns
| 1BSL01AE | SK Pharmaceuticals | SK Market | |
|---|---|---|---|
| 7D | 0% | 0.05% | 0% |
| 1Y | 0.9% | 15.0% | 1.5% |
Return vs Industry: 1BSL01AE underperformed the SK Pharmaceuticals industry which returned 15% over the past year.
Return vs Market: 1BSL01AE matched the SK Market which returned 1.5% over the past year.
Price Volatility
| 1BSL01AE volatility | |
|---|---|
| 1BSL01AE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in SK Market | 9.9% |
| 10% least volatile stocks in SK Market | 2.5% |
Stable Share Price: 1BSL01AE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 1BSL01AE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1953 | 207 | n/a | www.biotika.sk |
Biotika a.s. operates as a pharmaceutical manufacturing company in Slovakia and internationally. The company offers active pharmaceutical ingredients (API), including phenoxymethylpenicillin calcium, phenoxymethylpenicillin potassium, phenoxymethylpenicillin potassium granulated, and polymyxin B sulfate (non-sterile) substances; and pharmaceutical preparations for the human and veterinary applications. It is also involved in the contract manufacture of APIs comprising Gramicidin S hydrochlorid (non-sterile) and L-CYSTINE substances; and antibiotics.
Biotika a.s. Fundamentals Summary
| 1BSL01AE fundamental statistics | |
|---|---|
| Market cap | €16.10m |
| Earnings (TTM) | €369.09k |
| Revenue (TTM) | €16.18m |
43.6x
P/E Ratio1.0x
P/S RatioIs 1BSL01AE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BSL01AE income statement (TTM) | |
|---|---|
| Revenue | €16.18m |
| Cost of Revenue | €23.09m |
| Gross Profit | -€6.91m |
| Other Expenses | -€7.28m |
| Earnings | €369.09k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.53 |
| Gross Margin | -42.71% |
| Net Profit Margin | 2.28% |
| Debt/Equity Ratio | 0% |
How did 1BSL01AE perform over the long term?
See historical performance and comparison